NCT01761773View on ClinicalTrials.gov

A Single-Dose Study to Assess the Pharmacokinetics of Cabozantinib (XL184) Capsules in Subjects With Impaired Renal Function

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

April 30, 2013

Study Completion Date

July 31, 2014

Conditions

HealthyRenal Impairment

Interventions

DRUG

cabozantinib

3 20-mg strength capsules (60 mg dose) administered as a single oral dose on Day 1 of study participation.

Trial Locations (3)

32809

Orlando

33136

Miami

07753

Neptune City

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Exelixis

INDUSTRY